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Summary The in vitro deamination, cytotoxicity, cellular drug uptake, distribution and cellular pharmacology
in HL-60 cells of N'-hexadecyl-l-p-D-arabinofuranosykcytosine (NHAC), a lipophilic derivative of
arabinofuranosylcytosine (ara-C), were studied. Compared with ara-C, NHAC in liposomal formulations was
highly resistant to deamination, resulting in levels of formation of arabinofuranosyluracil 42 and ten times
lower in plasma and liver microsomes respectively. The cytotoxicity of NHAC was independent of both the
nucleoside transporter mechanism and the deoxycytidine (dCyd) kinase activity as demonstrated by co-
incubating NHAC with dipyridamole and/or dCyd. In ara C-resistant HL-60 cells NHAC was still cytotoxic,
requiring drug concentration only 1.6 times higher than sensitive cells. Uptake of NHAC was six times higher
and was not inhibited by dipyridamole. The pharmacokinetics of NHAC revealed that its intracellular half-life
is 4.8 times longer than that of ara-C. Ara-CTP formation and incorporation into DNA was up to 25-50
times lower than that of ara-C and contributed only marginally to the cytotoxic effects of NHAC. These
results indicate that, because of the significantly increased stability, the transporter-independent uptake and the
dCyd-kinase-independent cytotoxicity, NHAC might be active in ara-C-resistant cells.
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I-P-i-Arabinofuranosylcytosine (ara-C) is one of the most
effective agents in the treatment of acute myelogenous
leukaemia (Keating et al., 1982; Plunkett and Gandhi, 1993).
However, its usefulness is limited by its rapid deamination to
the biologically inactive metabolite l-p-D-arabinofuranosyl-
uracil (ara-U) (Ho and Frei, 1971). Thus, to be therapeutic-
ally effective, ara-C must be administered either continuously
for 5 days (Frei et al., 1969) or as high-dose regimens up to
3 gm2 (Momparler, 1974). In order to avoid or delay the
deamination of ara-C in vivo, a large number of NA-
derivatives of ara-C have been synthesised (Wempen et al.,
1968; Kanai and Ichino, 1974; Rosowsky et al., 1982) or
ara-C was used in combination therapies with deaminase
inhibitors such as tetrahydrouridine (Kreis et al., 1991) or
zebularine (Driscoll et al., 1991). Lipophilic ara-C derivatives
modified with long-chain fatty acids show strong anti-tumour
activity in murine tumour models (Aoshima et al., 1976;
Kataoka and Sakurai, 1980; Tsuruo et al., 1980). A related
5'-substituted liponucleotide, cytarabine ocfosfate, has
recently been approved for clinical use in Japan (Houlihan et
al., 1995). In a previous study we demonstrated that N-
acyl derivatives of ara-C incorporated into the membranes of
small unilamellar liposomes are active against murine L1210
leukaemia and B16 melanoma cells at concentrations 2-4
times lower than ara-C (Rubas et al., 1986). However, resis-
tance of the N'-acyl derivative N'-oleyl-l-p-i-arabino-
furanosylcytosine to enzymatic deamination to ara-U was
only partially achieved and suggested to be still insufficient in
a phase I/II study (Schwendener et al., 1989). For this reason
we synthesised the N'-alkyl-ara-C derivative N-hexadecyl-l-pf
D-arabinofuranosylcytosine (NHAC) (Schwendener and Schott,
1992). This compound has greater tumour-inhibitory effects
than ara-C in the L1210 tumour model at molar drug con-
centrations 16 times lower. NHAC also exerts a strong
cytotoxic effect at single dose schedules, suggesting a long-
lasting drug effect.
A major reason for treatment failure in leukaemia patients
is ara-C resistance. Possible mechanisms of ara-C resistance
that have been proposed include low levels of deoxycytidine
kinase (Chu and Fisher, 1965), increased catabolism by
cytidine deaminase (Steuart and Burke, 1971) and a
decreased number of nucleoside transport sites (Wiley et al.,
1982). The cellular uptake of ara-C is achieved by transporter
mediated facilitated diffusion (Plagemann et al., 1978).
Because of the lipophilicity of NHAC we postulate a
transporter-independent uptake mechanism as well as altered
behaviour in cellular pharmacokinetics.
In the present study, we investigated the deamination
kinetics of NHAC and ara-C in human plasma and mouse
liver microsomes. Furthermore, we evaluated the properties
of NHAC compared with ara-C by studying in vitro its
cytotoxicity in the human myeloid leukaemia cell line HL-60
and, in ara-C-resistant HL-60/ara-C cells, the cellular uptake,
the intracellular drug distribution and pharmacokinetics, the
rate of ara-CP formation and incorporation into DNA.
Materials and methods
Drugs
Ara-C, dipyridamole and 2'-deoxycytidine (dCyd) were pur-
chased from Sigma (Buchs, Switzerland). [5-3H-]Ara-C (30 Ci
mmol i) and custom-synthesised [5-3HNHAC (5.1 Ci mmol')
were purchased from Amersham (Amersham, UK). For all
incubations, ara-C was dissolved in phosphate-buffered saline
(PBS; 8 mM sodium phosphate, 1.5 mM potassium dihy-
drogen phosphate, 0.14 M sodium chloride, 2.6 mM potas-
sium chloride) with trace amounts of [53Hlara-C. NHAC
was given in a liposomal formulation as described in the
Liposome preparation section. NHAC was synthesised as
previously described (Schwendener and Schott, 1992). Tet-
rahydrouridine was a gift from the Drug Development
Branch of the National Cancer Institute (Bethesda, MD,
USA).
Cells
HL-60 promyelocytic leukaemia cells were obtained from the
American Type Tissue Culture Collection (ATCC CCL 240).
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The ara-C-resistant HL-60 cells (HL-60/ara-C) were a kind
gift from Dr Studzinski, UMD-New Jersey Medical School,
Newark, NJ, USA (Kolla and Studzinski, 1994). This HL-60/
ara-C sublime has been isolated and characterised by Bhalla
et al. (1984). The cells were grown in RPMI-1640 medium
(Gibco, Paisley, UK) supplemented with 10% heat-
inactivated fetal calf serum (FCS; PAA-Biologics, Lin7 Aus-
tma), 100 units ml 1 penicillin and 100 9ggmlV- streptomycin
in a humidified 5% carbon dioxide atmosphere. The
experiments were initiated in logarithmically growing cultures
at a density of 3-5 x 105 cells ml-'.
Liposome preparation
Small unilamellar liposomes of 100 ± 30 nm mean diameter
were prepared by filter extrusion as described by Hope et al.
(1985). Briefly, lipid mixtures composed of soy phosphatidyl-
choline (SPC), cholesterol, DL-a-tocopherol and NHAC at a
molar ratio of 1:0.2:0.01:0.1 were hydrated with PBS and
sequentially filtrated through Nuckepore (Costar, Sterico,
Dietikon, Switzerland) filters of decreasing pore size (I pum,
400 nm, 100 nm). Liposomes without NHAC, termed empty
liposomes, were used as control. All preparations
(2-40 mg ml-' SPC) were sterile filtered through 0.2 zm
filters (Acrodisc, Gelman, Ann Arbor, MI, USA) and stored
at 4C. Trace amounts of [5-3H]NHAC were added for detec-
tion and quantification.
Deamination studies
Fresh human plasma or freshly prepared mouse liver mic-
rosomes were incubated with [5'HJara-C (1 9lCi per sample)
dissolved in PBS or [5-3H]NHAC-liposomes either for
different time periods at a concentration of 2 9AM or with
increasing concentrations (0-1.33 mM) of the drugs for 3 h at
37C. Microsomal incubations were carried out in the
presence of 0.6 mM NADP, 3 mM glucose 6-phosphate, 0.6
units ml-' glucose-6phosphate dehydrogenase (Boehringer
Mannheim, Germany) and 4.6 mM magnesium chloride. To
inhibit further deamination, tetrahydrouridine (2 9AM) was
added after the incubation and the probes were ultrafiltrated
using Diaflo YM membranes (Amicon, Lexington, MA,
USA; M, 10 000 cut-oft). The filtrates were analysed for ara-
U by ion-exchange high performance liquid chromatography
(HPLC) on a Partisil SCX column (Knauer, Berlin, Ger-
many) using potassium dihydrogen phosphate (15 mM,
pH 2.5) as elution phase at a flow rate of 1.2 ml min'
(Spriggs et al., 1987). The fractions containing ara-U were
pooled and quantified by scintillation counting. Protein con-
centration in the microsomes was determined as described by
Bradford (1976). The final protein concentration in the pro-
bes was 3.4mgml-'.
Cytotoxicity assays
HL-60 cells were counted and seeded in 96-well plates
(3 x I Ocells ml-'). Then the cells were exposed to various
concentrations (0-200 9AM) of ara-C, NHAC or empty
liposomes in the presence or absence of 20,UM dipyridamole
and/or 209AMdCyd for 24 h at 37C (5% carbon dioxide).
Dipyridamole and/or dCyd were added 5 min before drug
exposure. After incubation the medium was removed, the
cells washed once and resuspended in fresh, serum-free
RPMI-1640 medium. The cell survival fractions were deter-
mined with the 344,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MIT) dye reduction assay as described by
Mosmann (1983). All experiments were repeated four times.
Accordingly, the cytotoxic effects of ara-C and liposomal
NHAC against HL-60/ara-C-resistant cells were measured
with the MTT assay but without any additives. Cell growth-
inhibitory concentrations (IC50 and IC20) were caculated
from interpolations of the graphical data.
Drug uptake
HL-60 cells (2 x 106 cells per well) were incubated in 24-well
plates with increasing concentrations up to 200 9M of
(5-3HJara-C or [5-3HINHAC (2 9ACi per sample) in the
presence or absence of the nucleoside-transport blocking
agent dipyridamole (20gM) for 3 h at 37C (5% carbon
dioxide). Dipyridamole was added 5 min before drug
exposure. After washing twice with cold PBS, total drug
uptake was determined by scintillation counting. All
experiments were performed in triplicate.
Cellularpharmacokinetics
HL-60 cells (5 x 106 cells per well) were incubated with 2 9AM
[5-Hjara-C or [5-3'HNHAC (2 9Ci per sample) for 2 h at
3TC (5% carbon dioxide). Cells were washed twice with cold
PBS to remove unbound drug. The incubations were con-
tinued in RPMI medium and stopped after different time
periods up to 3.5 h to determine peak concentration, time-
dependent total drug uptake and l-P-D-arabinofuranosyl-
cytosine triphosphate (ara-CTP) formation. Intracellular half-
lives were calculated by linear regression of semilogarithmic
concentration vs time plots. The area under the curve (AUC)
was determined from these plots using proFit software
(Quantumsoft, Zurich, Switzerland). All experiments were
performed in triplicate.
Cellular ara-CTPformation
HL-60 cells (5 x 106 cells per well) were incubated with in-
creasing concentrations of[5-HIara-C or [5-3HJNHAC (2 9Ci
per sample) for 2 h at 3TC (5% carbon dioxide). After
washing twice with cold PBS, the cells were lysed with 0.4 M
perchloric acid and centrifuged after 10 min (10 000 g for
2min). The supernatants were collected, neutralised with
IOM potassium hydroxide and centrifuged (12 000g for
10min). The resulting supematant was analysed for ara-CTP
by ion-exchange HPLC using a Spherisorb SAX column
(Phenomenex, Torrance, CA, USA) and 125 mM potassium
dihydrogen phosphate plus 75 mM trisodium citrate (pH4.6)
as elution buffer at a flow rate of 0.45 ml min-'. Ara-CTP-
containing fractions were pooled and analysed by scintilla-
tion counting. All experiments were performed in triplicate.
Incorporation into DNA
HL-60 cells (1.8 x 107 cells per well) were incubated with
2 9AM [5)H]ara-C or [5-3'HNHAC (25 9ACi per sample) for
different time periods at 3TC (5% carbon dioxide). After
washing twice with cold PBS, DNA was extracted as de-
scribed by Spriggs et al. (1987). For the quantification of
incorporated drug, the DNA was collected by filtration
through Whatman GF/C filters (Whatman, Maidstone, UK).
The filters were extensively washed with cold ethanol and the
amount ofincorporated drug quantified by scintillation coun-
ting (Momparler et al., 1990).
Reults
Deamination
Figure I shows the kinetics of deamination of liposomal
NHAC and ara-C in human plasma (Figure la) and mouse
liver microsomes (Figure lb). NHAC was almost completly
resistant to deamination in plasma, resulting in a 42-fold
reduction in ara-U formation after 4 h incubation. Expressed
as a percentage, 84% of ara-C was deaminated to ara-U,
whereas only 2% of NHAC was deaminated to ara-U. In the
concentration-dependent study using freshly prepared mouse
liver microsomes, NHAC was deaminated to ara-U at a
slower rate and at concentrations 5-10 times lower than
ara-C. These results demonstrate that NHAC is highly resis-
tant to deamination.
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Figwe 1 Deamination kinetics of ara-C and NHAC in human
plasma (a) and mouse liver microsomes (b). (a) Fresh human
plasma was exposed for various times to 21FM ara-C (U) or
NHAC (0). (b) Various concentrations of ara-C and NHAC
were incubated with freshly prepared mouse liver microsomes.
Symbols = mean from two separate experiments; bars = s.d.
Where no error bars are seen, they are smaller than the size of
the symbols.
Cytotoxicitv in HL-60 cells
The cytotoxicity of NHAC and ara-C in HL-60 cells in the
MTT dye reduction assay after a continuous 24 h incubation
is shown in Figure 2a. As a negative control, the cytotoxicity
of empty liposomes without NHAC was determined. While
empty liposomes were not toxic to HL-60 cells at a lipid
concentration up to 0.4 mg ml-' SPC, corresponding to a
drug concentration in the drug-containing liposomes of
100 1AM NHAC, further increase in the lipid concentration to
0.8 mg ml-' SPC (corresponding to liposomes with 200 1AM
NHAC) led to a weak toxicity of the empty liposomes, as
demonstrated by a decrease in cell viability to 93% compared
with the untreated control cells. The cytotoxic effect of
NHAC-liposomes resulted in an IC50 value of 47.0 ± 6.2 1M
and an IC20 value of 13.2 ± 2.7 1M respectively. Ara-C was
more toxic than NHAC at low drug concentrations up to
201AM with an IC20 of 1 g1M, whereas the IC50 value was not
reached in the concentration range up to 2001AM during a
24 h drug exposure. Therefore for ara-C the IC20 values are
given instead of the IC% values.
Figure 2b-d shows the cytotoxicity assays of ara-C and
NHAC in HL-60 cells in combination with dipyridamole
(Figure 2b), dCyd (Figure 2c) and dipyridamole plus dCyd
(Figure 2d). Dipyridamole is a well-characterised nucleoside
transporter-blocking agent (King et al., 1984). As shown in
Figure 2b, the cytotoxicity of ara-C was strongly reduced by
dipyridamole (IC20=215± 131M and IC50>40011M), but
not with NHAC (IC20= 9.3± 1.3gM and
IC = 48.9 ± 3.1 g1M), indicating a nucleoside transporter-
independent uptake mechanism for NHAC (see also Figure
4). dCyd is the physiological substrate of dCyd-kinase and a
Celdu pharmaogy Of N-dgc_aC
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competitive inhibitor of ara-C phosphorylation (Coleman et
al., 1975). As shown in Figure 2c, the cytotoxicity of ara-C
was significantly decreased by the addition of 20 iM dCyd
S min before drug exposure. Thus, the IC2! value for ara-C
increased from 0.9 ± 0.1 1AM to 186.3 ± 4.0tLM when the cells
were pretreated with dCyd. In contrast, the cytotoxic effect
of NHAC was not affected by dCyd, indicating that the
mode of action of NHAC is independent to a great extent of
the phosphorylation pathway. The combination of
dipyridamole plus dCyd led to a further decrease in the
cytotoxic effect of ara-C. As shown in Figure 2d. an ICO
value for ara-C was therefore not reached at drug concentra-
tions below 200 1AM. In contrast, the cytotoxicity of NHAC
was not influenced by pretreating the HL-60 cells with
dipynrdamole plus dCyd, resulting in an IC50 value of
46.9 ± 3.4 1M, which is identical to the IC50 value of the
NHAC treatment without additives (Figure 2a) or the treat-
ment with dipyridamole or dCyd alone (Figure 2b and c).
Cvtotoxicitv in ara-C-resistant HL-60 cells (HL-60/ara-C)
Figure 3 shows the concentration-dependent cytotoxic effects
of ara-C and liposomal NHAC on the HL-60/ara-C-resistant
cells. However, it should be noted that direct comparison of
the HL-60 and HL-60/ara-C cell lines is difficult because of
their different growth characteristics. The doubling time was
found to be 30h for the HL-60 cells and 22 h for the
HL-60/ara-C cells. NHAC was more cytotoxic than ara-C to
HL-60/ara-C cells in the concentration range up to 2001AM.
However, compared with the ara-C-sensitive HL-60 cells the
cytotoxic effect of NHAC was slightly reduced, requiring
77.0± 2.9 1M to reach the ICO as compared with 47.0+
6.21M for the sensitive HL-60 cells and 15.4 ± 2.3 1AM to
reach the ICv as compared with 13.2 ± 2.7 1M. Ara-C, on
the other hand, was, as expected, significantly less cytotoxic
to resistant HL-60/ara-C cells, not reaching an IC5o value
below 2001AM and resulting in a IC20 of 52.2 ± 4.71M com-
pared with 0.9 ± 0.1 1M for the sensitive HL-60 cells (Figure
2a).
Cellular drug uptake
Figure 4 summarises the cellular uptake of ara-C and
liposomal NHAC in HL-60 cells in the presence and absence
of the nucleoside transporter-blocking agent dipyridamole.
The uptake of ara-C was slightly higher than that of NHAC
at low drug concentrations up to 101AM, however it was
highly sensitive to dipyridamole. Thus, by adding
dipyridamole 5 min before drug exposure, the uptake of ara-
C decreased by a factor of 2.5-28 depending on the drug
concentration. The uptake of NHAC, in contrast, was not
blocked by dipyridamole, resulting in a 4- to 15-fold higher
drug accumulation over the whole concentration range of
1-2001M, and in a 1.5- to 6-fold higher uptake compared
with ara-C alone in the range 20-2001M. In contrast to
NHAC, the uptake of ara-C revealed typical
Michaelis-Menten kinetics, reaching saturation at
40-601AM. These results provide evidence that the uptake of
lipophilic NHAC is not dependent on the nucleoside trans-
port mechanism and the number of transport sites per cell.
Cellularpharmacokinetics
Table I summarises the parameters of the intracellular phar-
macokinetics of ara-C, NHAC and ara-CTP determined by
incubating the cells for various periods in drug-free medium
after 2 h drug exposure. All three compounds followed first-
order kinetics during incubation periods of up to 3.5 h. The
intracellular half-life for ara-C was 1.55 h, whereas the half-
life for NHAC was 4.8 times longer, indicating a depot effect
of the drug in the cellular membranes. The half-life for
ara-CTP formed from NHAC was 1.8 times longer than that
from ara-C. The longer half-life of ara-CTP originating from
NHAC may be caused by the slow dealkylation of NHAC to
ara-C and its subsequent phosphorylation to ara-CTP. The
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Fugwe 2 Cytotoxicity assays by MTT dye reduction in HL-60 cells. Cells were incubated with ara-C (U), NHAC-liposomes (0)
or empty liposomes (*) for 24 h at 3TC (5% carbon dioxide) at a concentration range from 1 to 200pM (a). (b) The cells were
additionally incubated with 20FM dipyridamole for 5 min before drug exposure. (c) dCyd 20pM was added and in d a combination
of 20 iLm dipyridamole and 20FM dCyd was used 5 min before drug exposure. Symbols = mean from four separate experiments;
bars = s.d.
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Fgwe 3 Cytotoxicity assays by MTIT dye reduction in the
ara-C-resistant HL-60/ara-C cells. Cells were incubated with ara-
C (U) or NHAC-liposomes (0) for 24h at 37C (5% carbon
dioxide) at a concentration range from I to 200 FM. Symbols =
mean from four separate experiments; bars = s.d.
AUC of NHAC was 5.9 times that of ara-C, whereas the
AUC of ara-CTP formed from ara-C was 3.6 times greater
than formed from NHAC. Phosphorylated metabolites of
NHAC (e.g. NHAC-triphosphate) were not detected by the
method used for the measurement of ara-CTP.
Ara-CTPformation
The concentration-dependent formation of ara-CTP from
ara-C and liposomal NHAC is shown in Figure 5.
Significantly higher amounts of ara-CTP were formed from
ara-C, reaching levels 5-90-times higher than those formed
from NHAC. In contrast to NHAC, ara-C again revealed
Drug concentration (gm)
Fugwe 4 Uptake of ara-C and NHAC in HL-60 cells. Cells
were exposed to various concentrations of ara-C or NHAC for
3 h at 3TC (5% carbon dioxide) in the presence or absence of the
nucleside transporter-blocking agent dipyridamole (20pM).
Dipyridamole was added 5 min before drug exposure. Ara-C (U),
ara-C plus dipyridamole (-), NHAC (0), NHAC plus
dipyridamole (0); Symbols = mean from three separate
experiments; bars = s.d. Where no error bars are seen, they are
than the size of the symbols.
Michaelis-Menten kinetics, reaching saturation at 40 M,
whereas ara-CTP formation from NHAC increased with
linear kinetics, not reaching saturation below 200 pM. The
molar ratios of ara-CTP formed by ara-C and NHAC were
for 1 Lm and 209AM drug concentration 90 and 39 respec-
tively. In the concentration range of 1-60 9M, which is
cytotoxic to HL-60 cells (Figure 2a), the amounts ofara-CUP
formed from NHAC were 90 to 16times lower. These low
ara-CTP concentrations are not likely to be sufficient to
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Tabie I Parameters of intracellular pharmacokinetics of ara-C,
NHAC and ara-CTP in HL-60 cells
Determbuaion Drug Total rg Ara-CTP
Peak drug CoMCentrationb Ara-C 4.0±0. 3.3±0.1c
(pmol 10-' cells) NHAC 14.0± 1.0 1.9±0.1
Intracellular half-life Ara-C 1.55±0.11c 1.51±0.21c
(h) NHAC 7.42±0.58 2.69±0.25
AUCe Ara-C 7.58 5.14
(pmol 10-6cellsh) NHAC 44.66 1.41
'Ara-C was given in PBS solution and NHAC as a hposomal
pepaiaw bPeak drug concentratos we determined after 2h
incubationwith2pmara-CorNHACinHL-60cell.cMean±sd. from
three determinations. dIntacellular half-ives of ara-C, NHAC and
ara-CT? in HL-60cellsafteriubation with 2pm ara-C orNHAC for
2 h. After incubation, the cells werashe to remove unbound drug
andtheincubationcontmued forvaros timesupto 3.5 h. 'Areaunder
the curve (AUC) as calculated from three determinations fitted by
first-order kinetics. Cells we incubated for 2 h with 21m ara-C or
NHAC, washed to remove unbound drug and icubated in drug-free
medium up to 3.5 h.
Taie I DNA incorporation after incubaton with ara-C orNHAC'
DNA-incorporated dr (pmol 10-' cells)
Drug I h 3h 6h 24h
Ara_Cb 1.73 2.91 3.44 0.56
NHACC 0.07 0.11 0.16 0.16
'DNA incorporation of metaboites formed after incubatio of
HL-60celswith2gmara-C orNHAC forvarious imes. bAna-CinPBS
sohition. 'NHAC in liposomes.
contribute sniicantly to the cytotoxic activity ofNHAC, as
shown in the MTT dye reduction assays (Figure 2a and c).
Incorporation into DNA
As shown in Table II, incorporation of metabolites into
DNA after incubation with ara-C for up to 6 h was indepen-
dent of the incubation time and on average 25 times higher
than after NHAC incubation. After 24 h however, the incor-
poration into DNA of metabolites orginating from ara-C
was rdud, which can be explained by the higher cytotoxic
effect on the HL-60 lls of ara-C at the concentration of
2#zm (Figure 2a).
In the present study, the cellular pharmacology of a
liposomal preparation of NHAC, a new lipophilic alkyl
derivative ofara-C, was investigated. Since the N4-acyl-ara-C
derivatives, including N-behenoyl-ara-C, have been con-
sided as prodrugs which are actvted through metaboEsa-
tion to ara-C followed by phosphorylation to ara-CTP (Ueda
et al., 1983), we first studied whether the mechanism of
cytotoxicity of the N4-alkyl-ara-C derivative NHAC is the
sam as that ofother cytidine analogue The effects ofara-C
on DNA synthesis and thus its cytotoxic activity are
gnrally explained by two mecaisms. In the first, the
cytotoxic effect is produced by inhibition of DNA
polymrase by ara-CP through enzyme competition with
endogenous deoxy-CTP (Furth and Cohen, 1968; Momparler
et al., 1990). The incorporation of ara-CTP into DNA as a
strnd brek-inducing nucleotide is the second mechanism
and does not exclude the inhibition of DNA polymerase.
Kufe and collaborators (Major et al., 1981; Kufe et al., 1984)
have demonstrated in their studies that the extent of ara-C
incorporation into DNA is the most powerful predictor of
cytotoxicity.
Our results with NHAC indicate, however, that although
small amounts of ara-C and ara-CP are derived from
NHAC (Figure 5), these low concentrations of ara-CP and
DNA-incorporated metabolites (Tables I and II) are unlikely
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F e 5 Ara-CTP formation in HL-60 cells. Cells were exposed
to various concetrations of ara-C (U) or NHAC (D) for 2 h at
3TC (5% carbon dioxide). Ara-CTP concentration was deter-
mined by HPLC analysis of cell lysate supernatants. Symbols =
mean from three separate experiments; bars = s.d
to be exclusively responsible for the cytotoxic effects of
NHAC in HL-60 cells. The fact that NHAC was still
cytotoxc in the ara-C-resitant HL-60/ara-C cells, requiring
only a 2-fold higher drug concentration to reach the ICso
value, provides further evidence that other mechanisms of
action are responsible for the cytotoxic activity of NHAC.
The maintenance of the cytotoxc activity in the ara-C-
resistnt cells indicates that NHAC might still be active in
ara-C-resistant leukaemias in which high activity of cytidine
daminase, decreased numbers of nuclede transport sites,
low deoxycytidine kinase activity and high deoxycytidine
triphosphate pools are causing ara-C resistance (Steuart and
Burke 1971; Tattersall et al., 1974).
The cdlular uptake of NHAC could not be saturated at
drug concentrations up to 200gm and was again, in contrast
to ara-C, independent of the number of nucleoside transport
sites, suggesting that drug uptake is achieved by a passive
diffusion process mainly resulting from the lipophilic proper-
ties of NHAC rather than by a transporter-mediated, active
mechanism. Thus, the uptake of NHAC in leukaemia cells
might be explained by fusion of liposomes with the cellular
membranes, by direct transfer of NHAC from the liposomes
to the cell membranes or by liposome phagocytosis.
Probably the most significant advantage of NHAC over
ara-C consists in its greatly improved stability against
deamination, which might be responsible for the difference in
cellular pharmacological properties such as the longer in-
tracellular half-life (Table I). These properties allow NHAC
to be administered at lower doses than an-C to obtain better
anti-tumour effects in vivo (Schwendener and Schott, 1992).
The possibility of producing large batches of sterile and
stable drug-containing liposomes (Schwendener, 1992) pro-
vides the opportunity to enter cinical studies with NHAC.
Owing to the high lipophilicity of the NHAC molecule, it is
essential to incorporate NHAC into liposomes in order to
obtain a physiological drug formulation. The liposomes
themselves and their size have no significant effect on the
uptake of NHAC in vitro (data not shown). The release of
NHAC from the hposomes and its interactions with blood
components have been studied in detail and the results will
be reported separately (Horber et al., 1995).
In conclusion, our study strongly suggests that NHAC is
able to overcome ara-C resistance by circumvention of the
major reasons for treatment failure among leukaemia
patients. Thus, NHAC is cytotoxic independently of the
nucoside transport mechanism and the dCyd kinase activity
in HL-60 cells and it still retains its activity in ara-C-resistant
HL-60/ara-C cells. Furthermore, the cellular uptake of
liposomal NHAC is higher than that of ara-C and indepen-
dent of the nucleoside transport hanism. Long-chain
alkylation of the amino group of ara-C provides excellent
r_
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protection against deamination and inactivation to ara-U.
Although the exact mechanism of action has not yet been
elucidated and further pharmacological studies are required.
nevertheless it seems to be obvious that the mechanism of
cytotoxicity of NHAC is very different from that of ara-C or
the M-acyl-ara-C derivatives.
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